The U.S. Food and Drug Administration (FDA) has approved an important update to the prescribing label for Afrezza, an inhaled insulin used in adults with diabetes. The new label provides clearer starting dose guidance for patients who are transitioning from subcutaneous mealtime insulin, including multiple daily injections and insulin pump therapy.
This update, announced by MannKind Corporation in January 2026, aims to reduce uncertainty for healthcare providers and patients when converting from injected insulin regimens to Afrezza. With improved dosing recommendations supported by clinical trial data, the revised label represents a meaningful step forward in simplifying insulin transitions and optimizing postprandial glucose control.
In this article, we break down what Afrezza is, what the FDA label update means, how the new dosing conversion works, and why this change matters for people living with diabetes and the clinicians who care for them.
Afrezza is the only ultra rapid-acting inhaled insulin currently approved by the FDA. Unlike traditional mealtime insulin that is injected under the skin, Afrezza is inhaled through a small, portable device at the start of a meal.
The insulin is delivered using MannKind’s proprietary Technosphere technology. Once inhaled, insulin particles are absorbed through the lungs and enter the bloodstream very quickly. This allows Afrezza to act faster than many injected rapid-acting insulins and to exit the body sooner as well.
Key characteristics of Afrezza include:
Because of these properties, Afrezza more closely mimics the body’s natural insulin response to food. For some adults with diabetes, this can translate into improved postprandial glucose control and greater flexibility around mealtime insulin use.
Transitioning from one insulin regimen to another is rarely simple. Subcutaneous insulin injections and insulin pump boluses deliver insulin differently than inhaled insulin, and the dosing units are not directly interchangeable.
Historically, one of the main barriers to wider Afrezza adoption has been uncertainty around how to convert doses safely and effectively from injected mealtime insulin. Providers often needed to rely on clinical judgment, trial and error, and close glucose monitoring to find the right Afrezza dose.
Without clear starting dose guidance, patients faced risks such as:
The FDA-approved label update directly addresses this gap.
The updated Afrezza prescribing information now includes a clear table that outlines recommended starting mealtime doses when switching from injected insulin or insulin pump bolus dosing.
These recommendations are intended for adult patients initiating Afrezza and are designed to support a clinically appropriate and safe transition.
According to MannKind, the revised label was supported by modeling data, in vivo results from the Dose Optimization study, and findings from the INHALE-3 clinical trial. These studies demonstrated improved postprandial glucose outcomes when patients used the now-approved conversion dosing.
Here is a simplified explanation of the new dosing guidance:
| Current Subcutaneous Mealtime Insulin Dose | Recommended Starting Afrezza Dose |
|---|---|
| Up to 3 units | 4 units |
| 4 to 5 units | 8 units |
| 6 to 7 units | 12 units |
| 8 units or more | 16 units |
This table gives healthcare providers a clear and standardized starting point when switching patients from injections or pumps to Afrezza.
It is important to note that these are starting doses. Individual patients may still require dose adjustments based on blood glucose response, meal size, carbohydrate intake, and overall diabetes management goals.
The FDA label change was not made in isolation. It was supported by both modeling data and clinical trial evidence.
The Dose Optimization study evaluated how different Afrezza conversion doses impacted glucose control after meals. The results helped identify dosing ranges that more consistently achieved target postprandial glucose levels when patients transitioned from injected insulin.
The INHALE-3 trial further demonstrated improved postprandial glucose outcomes using the updated conversion dosing. Patients who switched using the now-approved guidance experienced better glucose control after meals compared to earlier conversion approaches.
Together, these data provided the FDA with sufficient evidence to approve the updated label and formally incorporate the dosing guidance into Afrezza’s prescribing information.
For clinicians, the updated label simplifies decision-making and reduces uncertainty when initiating Afrezza. Instead of estimating conversion doses or relying solely on experience, providers now have FDA-endorsed guidance to support safe initiation.
Benefits for healthcare professionals include:
Dr. Kevin Kaiserman, Senior Vice President and Therapeutic Area Head for Diabetes at MannKind, noted that the update is expected to support appropriate initiation of therapy while reinforcing Afrezza’s established clinical profile.
For adult patients with diabetes who are considering Afrezza or who are already using it, the updated label can make the transition process smoother and less intimidating.
Potential patient benefits include:
Patients switching from multiple daily injections or insulin pumps may feel more reassured knowing that their starting dose is based on FDA-reviewed clinical data rather than guesswork.
While Afrezza offers unique advantages, it is not appropriate for everyone. The updated label does not change the existing safety profile or contraindications.
Afrezza is contraindicated in:
Acute bronchospasm has been observed in patients with asthma and COPD. For this reason, all patients must undergo a detailed medical history, physical examination, and spirometry testing before starting Afrezza.
Afrezza has been associated with a small decline in lung function over time, measured by FEV1. Pulmonary function should be assessed:
If a patient experiences a decline of 20 percent or more in FEV1 from baseline, discontinuation should be considered.
As with all insulin products, hypoglycemia is the most common adverse reaction associated with Afrezza. Severe hypoglycemia can be life-threatening and requires prompt recognition and treatment.
Patients should be educated on recognizing symptoms of low blood sugar and on appropriate glucose monitoring practices, especially during periods of insulin adjustment.
Patients with type 1 diabetes must always use Afrezza in combination with basal insulin. In clinical trials, diabetic ketoacidosis occurred more frequently in Afrezza-treated patients with type 1 diabetes compared to comparator treatments.
Patients at higher risk for DKA, such as those with acute illness or infection, may require increased glucose monitoring or temporary discontinuation of Afrezza.
The FDA’s approval of updated Afrezza dosing guidance reflects a broader trend toward patient-centric diabetes management. As treatment options expand, clarity around how to use them safely becomes just as important as innovation itself.
By addressing one of the most common barriers to Afrezza adoption, MannKind and the FDA have taken a step toward making inhaled insulin a more accessible and practical option for appropriate patients.
This update also highlights the growing role of real-world data, modeling studies, and post-approval clinical trials in refining how medications are used long after they first reach the market.
The FDA approval of updated Afrezza label dosing guidance is a meaningful development for both clinicians and adult patients with diabetes. Clear starting dose recommendations can reduce uncertainty, improve safety, and help patients achieve better postprandial glucose control when transitioning from injected mealtime insulin.
While Afrezza is not suitable for everyone, this update strengthens its role as a viable alternative for selected patients seeking a rapid-acting, needle-free insulin option.
As always, treatment decisions should be individualized and made in close consultation with a qualified healthcare provider.
MannKind Corporation press release
This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any changes to your medication, insulin regimen, or diabetes management plan.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.